Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com



Why Did The Vanguard Group Inc. Increased Its Shares To Almost $6 Million In BPMX – CWEB.com


Institutional investors currently hold major shares in BioPharmX Corporation(BPMX) stock. Majority of the recent share have been purchased by Vanguard Investment firm on 5-13-2018
BioPharmX Corporation (BPMX) stock was most active stock of Wall Street Market on Tuesday. BPMX moved -1.77% to 0.19. BPMX received interesting focus from Active Investors and it has been trading on front line as seeing to it recent volume.
Statistic show the size of the acne treatment market worldwide in 2016 and a forecast for 2025, in billion U.S. dollars. In 2016, the global acne treatment market was worth some 4.9 billion dollars and was expected to grow to over 7 billion by the end of 2025.
Statistic also show the market value of skincare products in Great Britain from 2009 to 2016. The total value of the skincare market in December 2016 was measured at approximately 2.16 billion British pounds
Owner NameDateShared HeldChange (Shares)Change (%)Value (in 1,000s)
VIVO CAPITAL, LLC05/13/201816,128,5152,328,57116.873,306
FRANKLIN RESOURCES INC05/13/20189,749,61500.001,999
VANGUARD GROUP INC05/13/20185,498,9183,541,971181.001,127
GEODE CAPITAL MANAGEMENT, LLC03/31/2018671,686347,719107.33138
VIRTU FINANCIAL LLC03/31/2018426,837426,837New88
BARCLAYS PLC03/31/2018362,900362,900New74
SUSQUEHANNA INTERNATIONAL GROUP, LLP03/31/2018181,335181,335New37
CITADEL ADVISORS LLC03/31/2018146,859146,859New30
MCF ADVISORS LLC03/31/2018105,629105,629New22
JANE STREET GROUP, LLC03/31/201896,94196,941New20
TWO SIGMA SECURITIES, LLC03/31/201893,39047,105101.7719
NORTHERN TRUST CORP03/31/201892,51800.0019
UBS GROUP AG03/31/201870,36736,614108.4814
LADENBURG THALMANN FINANCIAL SERVICES INC.03/31/201864,20000.0013
CREDIT SUISSE AG/03/31/201850,00050,000New10
HOLDERSSHARES
Increased Positions177,708,826
Held Positions715,447,095
Total Institutional Shares2733,878,519
On April 26th, 2018, BioPharmX reports its results for the quarter and year ended January 31st, 2018. For Q4 FY18, total operating expenses were $3.6 million, and net loss was $3.8 million.
For FY18, total operating expenses were $16.7 million, and net loss was $16.6 million. As of January 31st, 2018, cash and cash equivalents were $7.6 million.
BioPharmX Corporation (BPMX) has been working on the following pipeline for new products and FDA approvals.

HYDROPHILIC TOPICAL SYSTEM

1 Patent Issued, 21 Pending

STABILIZES
  • Hydrophilic: non-occlusive, non-oily
  • Non-lipophilic (oil-based)
  • Suitable for APIs degraded in water
FULLY SOLUBILIZES
  • Improves bioavailability
  • Not a suspension
  • Miscible w/ sebum
Higher penetration and targeted delivery
THERAPEUTICS
BPX-01-Acne
BPX-04-Rosacea
BPX-Retinoids
BPX-Combinations

INJECTABLE SYSTEM

1 Patent Pending

CROSSLINKED
  • Proprietary cross-linked injectable delivery system
SUSTAINED RELEASE
  • Prolonged release of biologics and small to mid-sized molecules
Suitable for aesthetics
AESTHETICS
BPX-02

ENCAPSULATION SYSTEM

3 Patents Issued, 4 Pending

ISOLATES
  • Separates hydrophilic APIs from boundary layer
ENCAPSULATES
  • Encapsulates between the hydrophilic and hydrophobic phases of emulsion
Emulsion feels smooth to the touch
COSMETICS

IODINE SYSTEM

1 Patent Allowed, 3 Pending

STABILIZES
  • Oral delivery of iodide and iodate
  • Patented formulation stabilizes iodine
TARGETS
  • Delivery to targeted mammary cells
  • Apoptotic and anti-proliferative effects
Commercially available product since 2014
WOMEN'S HEALTH
BPX-03
Women’s Health Asset for Strategic Partnerships
The patent (U.S. Patent No. 9,918,998), entitled "Pharmaceutical Tetracycline Composition For Dermatological Use," covers a topical composition comprised of minocycline or another tetracycline-class drug and a method for making such compositions. The patent also covers treatments of dermatological inflammation or infection using a minocycline composition. Current formulations protected by the patent include BPX-01 for the treatment of acne and BPX-04 for the treatment of rosacea.

This is the fourth U.S. patent issuance BioPharmX (BPMX) has received. Three earlier-issued U.S. patents protect the company's encapsulation delivery system, which can isolate the API. The most recent of these patents, U.S. Patent No. 9,901,586, entitled "Dosage Form Comprising an Active Ingredient and a Plurality of Solid Porous Microcarriers," was granted Feb. 27.
The US 9,918,998 patent protects tetracycline-class products carried by BioPharmX's innovative delivery system, which for the first time stabilizes and fully solubilizes these drugs to make them effective in a topical formulation. This includes products that use other tetracycline-class drugs as well as combination products that combine antibiotics with other drugs, for example retinoids.
"This patent protection is a significant milestone for BioPharmX," said President and Co-founder Anja Krammer. "It recognizes that our development of a topical tetracycline-class drug, something that has eluded the pharmaceutical industry since minocycline was first commercially used in the 1970s, is truly unique."

BioPharmX has successfully completed a phase 2b trial for BPX-01 for acne and is in phase 3 readiness. The company has reported positive interim results from a feasibility study for BPX-04 for rosacea and is preparing for a phase 2 trial.
Anthony Vendetti from Maxim Group maintained a Buy rating on BioPharmX Corp (NYSE: BPMX), with a price target of $1.50.

The Industry Biotechnology & Medical Research also suggest that  BioPharmX Corporation (BPMX) is currently the cheapest stock against major companies below:

PTIEPain Therapeutics Inc Com New4/23/1810.1530.46%
SNMXSenomyx Inc Com5/14/181.428.40%
VRTXVertex Pharmaceuticals Inc Com5/13/18157.240.81%
ARQLArqule Inc Com5/18/183.390.00%
ICLRIcon Plc Shs5/21/18125.740.00%
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators also suggest that BioPharmX Corporation (BPMX) , is undervalued.  
CWEB Analysts have Reiterate a Buy Rating for BioPharmX Corporation (BPMX)  and a Price Target of $7 within 12 months.
A possible partnership or major investment for  BioPharmX Corporation (BPMX)  is strongly possible in this coming month by big pharmaceutical company.
Read Full Article and Videos CWEB.com - Trending News, Blog, Shopping
Chart
BPMX data by YCharts

Comments

Post a Comment

Popular posts from this blog

CWEB - Many household products contain antimicrobial chemicals banned from soaps by the FDA

Image
Many household products contain antimicrobial chemicals banned from soaps by the FDA - CWEB.com Any antimicrobial chemicals in there? Home image via www.shutterstock.com. Erica Hartmann , Northwestern University This year marks 20 years since Hasbro was fined for false advertising , claiming their Playskool toys laden with the antimicrobial chemical triclosan would keep kids healthier. It is also the year when soap manufacturers will finally have to remove the chemical from their products. Triclosan is one example of a potentially hazardous chemical used in some antimicrobial products. The Food and Drug Administration recently banned it , along with 18 others chemicals, from hand soaps because of unacceptable risks to humans and the environment. Exposure to triclosan in general is linked with disruption of hormone function and the development of antibiotic resistance in bacteria. The FDA asked manufacturers to demonstrat...
Read more
Team Liquid emerged atop the League of Legends Championship Series Spring Split standings with a win on the concluding day of round-robin play. Liquid (14-4) won its third straight game, defeating TSM (5-13) to claim the top spot, while Cloud9 (13-5), which began the day tied for the lead, fell to FlyQuest (9-9). Third-place 100 Thieves (12-6) failed to capitalize on Cloud9's loss, losing to Dignitas (8-10) and staying third. Evil Geniuses (9-9) remained part of a three-way tie for fourth place by beating Counter Logic Gaming (6-12). Golden Guardians (9-9) was the third member of the tie after its win over Immortals (5-13). That tie proved significant because only the top four teams are guaranteed spots in the upper bracket of next month's playoffs. The Geniuses, FlyQuest and Guardians had to take part in a tiebreaker Sunday, and the Geniuses won out to clinch the fourth spot. FlyQuest and the Guardians will start next month's playoffs in the lower bracket. When...
Read more

Thousands of Amazon Employees Receive Layoff Mails, Jeff Bezos’ Surprise Visit at Meeting Sparks Fear Among Washington Post Staff

Image
Thousands of Amazon Employees Receive Layoff Mails, Jeff Bezos’ Surprise Visit at Meeting Sparks Fear Among Washington Post Staff : As the companies that drove the 10-year bull market adjust to a new reality, job cuts in the tech industry are piling up. On Wednesday, thousands of Amazon  (AMZN)employees received an email informing them that their position had been “eliminated” with immediate effect. In the most recent round of layoffs, which were first announced by […]
Read more